“Don’t Work on Things That Don’t Work”
At the time of this writing Kim Huard was one of Genentech’s Senior Scientists, and has spent a decade looking for new medicines. She spent eight years at Pfizer at the Groton and Cambridge sites before joining us in California. She’s currently a Director in the Discovery Chemistry department leading teams of scientists in pursuit…
The Post-Gleevec Era
Gleevec (imatinib) was the first tyrosine kinase inhibitor approved for the treatment of cancer and one of the first products to emerge from “rational drug design.” It’s invention changed chronic myeloid leukemia from an incurable death sentence to a manageable disease. Here’s a look back on the tremendous value it’s created over the last two…